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The essence of the immune system is built on two sepa-
rate foundation pillars: one is specific or adaptive immu-
nity which is characterized by relatively slow response
kinetics and the ability to remember. The other is
nonspecific or innate immunity exhibiting rapid response
kinetics but lacking memory. Lymphocytes are the key
players of the adaptive immune system. Each lymphocyte
expresses antigen receptors of unique specificity. Upon
recognizing an antigen via the receptor, lymphocytes pro-
liferate and develop effector function. Few lymphocytes
exhibit specificity for a given antigen or pathogen and
massive proliferation is usually required before an effector
response can be measured. Hence, the slow kinetics of the
adaptive immune system. Because a significant proportion
of the expanded lymphocytes survive and may maintain
some effector function after elimination of the antigen, the
adaptive immune system reacts faster when encountering
the antigen a second time. This is the basis of its ability to
remember. In contrast to the situation with lymphocytes,
where specificity for a pathogen is confined to few cells
that must expand to gain function, the cells and molecules
of the innate immune system are usually present in massive
numbers and recognize a limited number of invariant fea-
tures associated with pathogens (1). Examples of such pat-
terns include LPS, nonmethylated CG-rich DNA (CpG),
or double-stranded RNA, which are specific for bacterial
and viral infections, respectively. Most research in immu-
nology has focused on the adaptive immune system and
only recently has the innate immune system entered the
focus of interest. Historically, the adaptive and innate im-
mune system were treated and analyzed as two separate
entities that had little in common. Such was the disparity
that few researchers wondered why antigens were much
more immunogenic for the specific immune system when
applied with adjuvants that stimulated innate immunity
(2–4). However, the answer posed by this question is crit-
ical to our understanding of the immune system and for
comprehending the balance between protective immunity
and autoimmunity. This commentary tries to highlight a
few important links between the innate and adaptive im-
mune systems and how those may impinge on the course
of autoimmune diseases.
 
Association of Autoimmunity with Infection: Molecular Mim-
icry versus Aberrant Presentation of Self-Antigens.
 
It has long
been suspected that infections may be responsible for the in-
duction or precipitation of autoimmune diseases. Prominent
examples include an association of chlamydial infection
with heart disease or Coxsackie virus infection with type I
diabetes. A favored explanation for the potential of patho-
gens to cause autoimmunity is known as molecular mim-
icry. It is suspected that the pathogen shares T or B cell
epitopes with the host which may result in the induction of
a self-specific immune response upon infection (Fig. 1 a;
reference 5). This view is supported by the observation that
pathogen-specific T cell clones readily cross-react with de-
fined self-peptides (6) and sometimes cause disease in animal
models. Further support for the notion of molecular mim-
icry comes from the fact that when self-epitopes are dis-
played in a highly repetitive manner on viral surfaces, B cell
tolerance can be broken (7, 8). Nevertheless, it has recently
become evident that cross-reactivity between pathogen-
derived and self-derived antigens may not always be the cause
of infection-induced autoimmunity. Bystander T cell acti-
vation may in fact be as important a factor as molecular
mimicry (Fig. 1 a; references 9 and 10). Cell damage is an
inevitable side effect of any infection, be it through direct
pathogen-mediated cell destruction or through the action of
CTLs. Self-antigens are released during this process and
taken up and processed by macrophages and dendritic cells
(DCs). Simultaneously, these APCs become activated by
the above mentioned pathogen-associated “nonspecific”
factors such as LPS, CpGs, double-stranded RNA, or possi-
bly even cell debris. This would serve to increase their anti-
gen-processing ability, upregulate expression of costimula-
tory molecules, and trigger their migration to secondary
lymphoid organs where they efficiently prime T cell re-
sponses (11, 12). Surprisingly, it is not only pathogen-
derived structures that are able to nonspecifically trigger the
maturation program in DCs under these conditions. Factors
secreted by T cells also induce maturation of virtually all
DCs in lymphoid organs during viral infections (13). This
brings adaptive and innate immunity closer together and
further blurs their differences. Thus, generalized activation
of APCs may often be the cause for triggering self-specific
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Figure 1. Models for autosensitization of lymphocytes. (a) Self-antigens are transported to lymphoid organs where activation of self-specific lympho-
cytes occurs. On the left side is indicated that pathogens carrying B or T cell epitopes shared with the host may directly reach lymphoid organs for induc-
tion of an immune response. Alternatively, pathogens may infect DCs or are processed by them. Activated DCs subsequently migrate to lymphoid organs
and induce autoimmunity. On the right side is illustrated that pathogens may induce cell lysis, either directly or by activation of cytotoxic T cells. Self-
antigens (shown in yellow) are released during this process and are taken up and processed by local DCs. In addition, the DCs are stimulated by patho-
gen-associated patterns triggering their migration to lymphoid organs where autosensitization occurs. (b) Lymphocytes are recruited to the periphery,
where activation of self-specific lymphocytes occurs. Chemokines, such as BLC (triangles), are secreted by DCs which attracts B cells from lymphoid or-
gans and probably the peritoneum. B1 cells may be attracted preferentially under these conditions. These B cells together with additionally recruited T
cells and the BLC-producing DCs generate an environment ideal for activation of lymphocytes and autosensitization may occur locally. 
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lymphocytes and autoimmunity. This view is compatible
with a past observation that administration of LPS together
with thyroid extracts is able to overcome tolerance and trig-
ger autoimmune thyroiditis (14). Moreover, in a transgenic
mouse model, it was recently shown that administration of
self-peptide alone failed to cause autoimmunity unless APCs
were activated by a separate pathway (15). The link be-
tween innate immunity and autoimmune disease is further
underscored by the observation that LPS, viral infections, or
generalized activation of APCs delays or prevents the estab-
lishment of peripheral tolerance (16–18). In this way, innate
immunity not only enhances the activation of self-specific
lymphocytes but also inhibits their subsequent elimination.
 
Induction of Controlled Autoimmunity: A Challenge for Tu-
mor Therapy.
 
Rationalized manipulation of the innate im-
mune system to deliberately induce a self-specific T cell re-
sponse provides a means for T cell–based tumor therapy.
Hence, the focus of most current therapies is on the use of
activated DCs as antigen carriers for the induction of sus-
tained T cell responses (19). Similarly, in vivo activators of
the innate immune system, such as CpGs or anti-CD40 an-
tibodies, are being incorporated into the vaccines in order
to enhance their immunogenicity (20, 21). Considerable
success has been achieved by using these approaches. Nev-
ertheless, concommitant induction of autoimmunity is a
common side effect of tumor immunotherapy. Melanoma
therapy with tyrosinase-derived peptides is an example,
where normal melanocytes are sometimes destroyed by
CTLs leading to vitiligo (white patches in defined regions
of the skin). As long as the affected cell types are dispens-
able, this may not cause severe complications. However,
prolonged treatment of transgenic mice with DCs present-
ing the neo–self-antigen rapidly induces de novo formation
of lymph node–like organs in peripheral organs and lethal
autoimmunity, illustrating the fine line one has to walk for
CTL-based immunotherapy (22).
 
A Link between Chemokine Expression and Autoimmu-
nity.
 
In both mechanisms of autoimmunity discussed so far,
the self-antigen or mimic thereof is brought to B and T
cells in lymphoid organs, leading to their activation (Fig. 1
a). The paper by Ishikawa et al. in this issue (23) now
shows that the reverse may also occur, namely that lym-
phocytes are attracted to self-antigens in the periphery,
causing autoimmunity (Fig. 1 b). The molecule responsible
for this pathological migration of lymphocytes was B lym-
phocyte chemokine (BLC; CXCL13, B cell-attracting che-
mokine 1 [BCA-1]), a member of the chemokine family.
The physiological role of BLC is to orchestrate the genera-
tion and maintenance of B cell follicles in lymph nodes and
spleen, by attracting CXCR5 receptor–expressing B cells
(24). Upon stimulation by BLC, B cells produce lympho-
toxin 
 
 
 
 (LT-
 
 
 
), which is essential for the generation of fol-
licular DCs and formation of B cell follicles (25). Also, ex-
pression of secondary lymphoid tissue chemokine (SLC) is
induced which attracts T cells (in addition to BLC) and
leads to the formation of T cell regions adjacent to the B
cell follicles (26). Thus, BLC acts as a Spemann’s organizer
and its presence alone is sufficient for the induction of lym-
phoid organs in any part of the body. Indeed, overexpres-
sion of BLC in the pancreas of transgenic mice has previ-
ously been shown to induce local lymph node–like organs,
and insulitis, giving first indications that ectopic expression
of chemokines may be linked to autoimmunity (26). The
paper by Ishikawa et al. (23) now presents compelling evi-
dence for a role of BLC in inducing lupus-like symptoms
in (NZB 
 
  
 
NZW)F1 (BWF1) mice. In these mice, BLC
expression was increased up to 10,000-fold in organs such
as thymus and kidney, which are typically infiltrated by
lymphocytes. Surprisingly, the authors found that myeloid
DCs rather than follicular DCs were the major producers
of BLC in these afflicted organs, again indicating a pivotal
role for the DCs in regulating the balance between protec-
tive immunity and autoimmune disease. The molecular
mechanism for this disregulated expression and localization
of BLC so far remains unknown. Similarly as observed pre-
viously in the transgenic mouse expressing BLC in the pan-
creas (26), the authors here report large B cell–dominated
infiltrates in the thymus and kidney. Interestingly, B1 cells
were particularly frequent within these infiltrates, an obser-
vation that is consistent with an old hypothesis that B1 cells
are critical for disease in BWF1 mice. Also, the authors
demonstrate that B1 cells migrate more efficiently to BLC
than conventional B2 cells, which seems explained by the
fact that peritoneal B1 cells express higher levels of
CXCR5 than splenic B2 cells. Therefore, enhanced ex-
pression of BLC in DCs of BWF1 mice may attract B1 cells
and later also T cells, thus creating a lymphoid environ-
ment in a nonlymphoid organ — a situation tailored to
cause autoimmunity. B1 cells are discussed as the major
source of natural antibodies and are prone to produce au-
toantibodies. This is in part because they originate in the
peritoneum, which is secluded from many self-antigens
(27), and also because they may be selected rather than de-
leted by self-antigen (28). It is therefore conceivable that
the presence of elevated numbers of B1 cells in the thymus
or kidney of mice leads to the production of self-specific
antibodies involved in disease progression. It will be inter-
esting to see whether lymphoid-like organs observed in pa-
tients with Hashimoto’s thyroiditis or type I diabetes may
have a similar origin. Moreover, these observations offer
potential therapeutic opportunities for the treatment of
some autoimmune diseases. Instead of treating autoimmu-
nity by generalized immunosuppression, it may be suffi-
cient to block the action of BLC, or its downstream effec-
tor molecule LT-
 
 
 
. This could serve to inhibit chronic
inflammation of target organs and thereby prevent the vi-
cious circle of attracting lymphocytes to peripheral organs,
which in turn leads to autoimmunity and consequently en-
hanced target organ inflammation. As blocking LT-
 
 
 
 vir-
tually eliminates lymph node–like structures in the BLC
transgenic mouse model (26), this may indeed be an ave-
nue to follow.
In conclusion, the innate immune system is able to facil-
itate autosensitization in various ways (Fig. 1). Immune re-
sponses specific for self-antigens may be enhanced by in-
nate immunity mostly through APC activation. Thus, 
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APCs that carry self-antigen or a mimic thereof are stimu-
lated by components of pathogens, resulting in enhanced
presentation of self-antigens in lymphoid organs. On the
other hand, as shown in the present paper by Ishikawa et al.
(23), chemokines aberrantly produced in nonlymphoid or-
gans may be able to attract lymphocytes into the periphery.
Due to the capacity of chemokines to orchestrate together
with lymphocytes de novo formation of lymph node–like
organs, these lymphocytes may convert the usually poorly
immunogenic peripheral environment into an organ prone
to induce autoimmunity.
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